CureVac and Bayer Join Forces to Develop CVVC -V Candidate for COVID-19

“The need for COVID-19 vaccines is enormous. Therefore, we are delighted to be able to provide significant support to CureVac, a leader in mRNA technology, in the development and subsequent supply of its COVID-19 candidate vaccine,” said Stefan Oelrich. , Board Member and Chairman of Bayer Pharmaceuticals “We are committed to expanding our capabilities and infrastructure to help overcome the pandemic.”

“We are very excited to join forces with Bayer, whose expertise and infrastructure will help our CVnCoV candidate be available to as many people as possible,” said Dr. Franz-Werner Haas, CEO of CureVac. “As we develop CVnCoV, we are seeing positive results, and now we have a strong partner that will pass the vaccine to the people who need it as soon as we get the necessary permission from regulators.”

Under the terms of the cooperation agreement, CureVac will be the holder of the marketing authorization for the product, while Bayer will support CureVac in operations in European Union (EU) countries and selected additional markets. Bayer also has the opportunity to become a holder of a marketing authorization in other markets outside of Europe. The companies plan to use their strongest experience to enable CureVac to seamlessly deliver hundreds of millions of doses of CVnCoV worldwide once final approvals are received from regulators. Together, the two companies seek to play an important role in helping stop the COVID-19 pandemic.

CureVac is currently expanding its partner network to develop, manufacture, and distribute a COVID-19 vaccine candidate. 2020 November the company announced that it would expand its European production network in cooperation with Wacker and Fareva. 2020 Dec 14 The company achieved another major victory in CVnCoV development, launching the global flagship phase of Phase 2b / 3 clinical trials.